Drugs / V520
V520
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00849732 | Jun 2003 → Oct 2006 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00894114 | May 2003 → Jun 2009 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V520 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00849732 ↗ |
| Known as | MRKAd5 | “MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection” NCT00894114 ↗ |
| Known as | MRKAd5 HIV-1 gag vaccine | “MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection” NCT00894114 ↗ |
| Modality | Vaccine | “MRKAd5 HIV-1 gag vaccine” NCT00894114 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT00894114 ↗ |